Fifty 1 Labs and UAV Corp Announce Completion of Landmark Long COVID Trial

The collaboration between Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) has reached a pivotal milestone with the completion of the REVIVE Adaptive Platform Trial (NCT06128967), the largest Phase III study to date focused on Long COVID. This groundbreaking research, involving over 600 participants and conducted in partnership with prestigious institutions like Stanford and Duke, has demonstrated the efficacy of repurposed medicines in treating Long COVID, a condition that continues to affect millions globally with persistent symptoms following COVID-19 recovery.

Powered by Fifty 1 Labs' proprietary AI platform, the trial not only represents a significant leap forward in drug repurposing and personalized medicine but also aligns with the company's ambitious strategy to lead the $320.6 billion functional medicine market. The success of the REVIVE trial is a testament to the potential of combining advanced AI technology with medical research to accelerate drug discovery and customize treatments to meet individual patient needs, thereby setting a new standard in healthcare innovation.

The implications of this trial extend beyond the immediate benefits to Long COVID sufferers. It underscores Fifty 1 Labs' position as a frontrunner in biotechnology and wellness, showcasing its commitment to leveraging cutting-edge research and development to address some of the most pressing health challenges of our time. For more information on the REVIVE trial, visit https://clinicaltrials.gov/ct2/show/NCT06128967.